2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 813

Citrulline Specific CD4+ T Cells Exhibit a Th1 Memory Phenotype In Rheumatoid Arthritis Subjects and Their Ex Vivo Frequency Is Influenced By Both Disease Duration and Biologic Therapy
Abstract Number: 256

Classification Of Alignment By Self-Report Versus Radiograph Results In Unexpected and Discrepant Pain and Functional Outcomes
Abstract Number: 2436

Classification Of Axspa Based On Positive Imaging (Radiographs and/or MRI of the Sacroiliac Joints) By Local Rheumatologists Or Radiologists Versus Central Trained Readers In The DESIR-Cohort
Abstract Number: 1924

Cleveland Clinic Dual Energy X-Ray Absorptiometry Registry, A Web-Based Tool Designed For Efficient Collection Of Bone Density and Osteoporosis Related Clinical Risk Factor Data
Abstract Number: 2190

Clinical and Immunologic Description Of Pediatric Conditions With Interferon-Regulated Gene Signatures (Chronic Atypical Neutrophilic Dermatosis Lipodystrophy Elevated Tempature, Aicardi Goutieres Syndrome, Juvenile Dermatomyositis, Juvenile Systemic Lupus Erythematosus)
Abstract Number: 2073

Clinical and Prognostic Factors Associated With Survival In Mexican Patients With Idiopathic Inflammatory Myopathies
Abstract Number: 1437

Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study
Abstract Number: 1464

Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Abstract Number: 799

Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients
Abstract Number: 2508

Clinical and Serological Discordance In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
Abstract Number: 127

Clinical Application Of Pain Diagrams In Fibromyalgia
Abstract Number: 2020

Clinical Characteristics In Japanese Patients With IgG4-Related Disease
Abstract Number: 328

Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Abstract Number: 2478

Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital
Abstract Number: 2883

Clinical Characteristics of Rheumatoid Arthritis Patients with Secondary Sjögren’s Syndrome and Association with Joint Damage

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].